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Tumour stroma gene expression in biopsy specimens may obscure the expression of tumour parenchyma, hampering the predictive
power of microarrays. We aimed to assess the utility of fluorescence-activated cell sorting (FACS) for generating cell populations for
gene expression analysis and to compare the gene expression of FACS-purified tumour parenchyma to that of whole tumour
biopsies. Single cell suspensions were generated from colorectal tumour biopsies and tumour parenchyma was separated using FACS.
Fluorescence-activated cell sorting allowed reliable estimation and purification of cell populations, generating parenchymal purity
above 90%. RNA from FACS-purified and corresponding whole tumour biopsies was hybridised to Affymetrix oligonucleotide
microarrays. Whole tumour and parenchymal samples demonstrated differential gene expression, with 289 genes significantly
overexpressed in the whole tumour, many of which were consistent with stromal gene expression (e.g., COL6A3, COL1A2, POSTN,
TIMP2). Genes characteristic of colorectal carcinoma were overexpressed in the FACS-purified cells (e.g., HOX2D and RHOB). We
found FACS to be a robust method for generating samples for gene expression analysis, allowing simultaneous assessment of
parenchymal and stromal compartments. Gross stromal contamination may affect the interpretation of cancer gene expression
microarray experiments, with implications for hypotheses generation and the stability of expression signatures used for predicting
clinical outcomes.
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Gene expression microarray data have huge potential for cancer
research and treatment. Gene expression profiles have been used
to classify tumours (Bittner et al, 2000; Ramaswamy et al, 2001;
Selaru et al, 2002; Shipp et al, 2002), study the biology of tumour
progression and metastasis (Birkenkamp-Demtroder et al, 2002;
Ramaswamy et al, 2003), predict clinical outcomes (van de Vijver
et al, 2002; Huang et al, 2003; Iizuka et al, 2003), classify drug
resistance (Hofmann et al, 2002; Chang et al, 2003) and identify
novel drug targets (Marton et al, 1998). As the technology matures,
it is pushing towards mainstream clinical application (Gershon,
2004; Jarvis and Centola, 2005; Cardoso et al, 2008). Surmountable
challenges remain, such as standardisation and validation of the
competing platforms and analysis techniques. However, the
heterogeneity of clinical tumour samples remains a fundamental
problem which must be addressed (Winegarden, 2003). All cell
subpopulations in a sample contribute to the gene expression
profile. Relatively homogenous cell populations yield optimal
expression data, and increasing ratios of stromal cells may obscure
the gene expression of parenchymal cancer cells (Emmert-Buck
et al, 1996; Ross et al, 2000; Butte, 2002; Sugiyama et al, 2002).
Stromal gene expression may cause misinterpretation of data, with
important subtle cancer gene changes being masked by contam-
inating RNA, and increasing the potential for attributing incorrect
functional gene associations (Smith et al, 2003). However,
interactions between stromal cells and tumour parenchyma are
increasingly recognised as an important factor in tumour biology
and clinical outcome, and the delineation and retention of stromal
gene expression has considerable value (Fukino et al, 2007; Patocs
et al, 2007).
Laser capture microdissection (LCM) allows the selection of
specific cells from tissue and could potentially circumvent many of
these problems (Emmert-Buck et al, 1996). Sugiyama et al (2002)
examined the expression profile of LCM dissected tissue and whole
tissue. They demonstrated significant differences in expression
profiles, finding that the overall difference in the gene expression
profile was related to levels of stromal contamination. However,
LCM is a costly, laborious and highly skilled procedure which
yields small quantities of RNA, which renders clinical application
impractical (Liu, 2007). It has also been demonstrated by Michel
et al (2003) that the LCM process introduces a systematic bias into
gene expression profiles. Another problem encountered in the
estimation of stromal content histologically, and therefore by both
LCM and macrodissection, is the ‘reference trap’. A two-dimen-
sional microscopic view of a complex three-dimensional structure,
such as a tumour, leads to irreversible qualitative and quantitative
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sloss of information (Nyengaard, 1999). This means that fractions of
cells can be grossly under- or overestimated if unbiased sampling
methods (i.e. stereological methods) are not used.
Fluorescence cytometry (FC) and fluorescence-activated cell
sorting (FACS) allow simultaneous quantitation and multipara-
metric assessment of the phenotype of cells by staining with
fluorochrome-conjugated antibodies (Afanasyeva et al, 2004).
These are generally used to examine or sort peripheral blood
samples (Waguri et al, 2003), to identify tumour cells in malignant
effusions, to isolate clones and infrequently for the separation of
specific cell populations from solid tissue (Afanasyeva et al, 2004;
Suzuki et al, 2004). Advances in laser technology, speed of sorting
and range of fluorochromes, make FACS a potentially useful
method for identifying and purifying cell populations from solid
tumours for analysis. Fluorescence-activated cell sorting over-
comes many of the problems associated with LCM and macro-
dissection, by allowing systematic sampling of a large number of
parenchymal tumour cells, allowing confirmation of the purity of
targets and potentially, a better average of gene expression in
cancer cells. We aimed to evaluate the feasibility of using FACS for
producing homogenous cell populations for gene expression
microarray analysis of colorectal tumour samples. Specifically,
we wished to compare the differences in gene expression profiles
elicited from whole tissue and sorted cells.
MATERIALS AND METHODS
Colorectal carcinoma tissue
Colorectal carcinoma (CRC) tissue samples were obtained, with
informed consent, from patients undergoing curative bowel
resection (Table 1). All patients were Irish Caucasians. None of
the patients received preoperative chemotherapy or radiotherapy.
Three primary cancers were used to compare the gene expression
of sorted cells and whole tumour samples, after optimisation of our
FACS methodology. Collection of tissue was approved by the
Clinical Research Ethics Committee of the Cork Teaching
Hospitals.
Generation of a single cell suspension from colorectal
cancer tissue
Tumour samples were washed in Dulbecco’s modified Eagle’s
medium (DMEM; BioWhittaker, Wokingham, UK) and macro-
scopic necrotic tissue was excised with a scalpel and washed in
DMEM. A portion of the biopsy was immediately snap frozen in
liquid nitrogen and stored at  801C until RNA extraction and
approximately 1g of tumour tissue was mechanically disaggre-
gated, and subsequently enzymatically digested with bovine
collagenase II, IV (Sigma-Aldrich, Dublin, Ireland) and DNAse I
(Roche, Clarecastle, Ireland) at concentrations of 2 and 1mgml
 1,
at room temperature (221C) for 45–60min. This mix was then
filtered through 70mm pore mesh (Becton Dickinson, Oxford,
UK). All suspensions were generated under standardised environ-
mental conditions, being kept at 41C, except for the enzyme
digestion stage.
Flow cytometry
Dissociated cells in suspension were incubated on ice with mouse
anti-human epithelial antigen (HEA) monoclonal antibody (mAb)
conjugated with FITC (clone BER-EP4; Dako, Glostrup, Denmark),
anti-CD14 mAb conjugated with phycoerythrin (PE) and anti-
CD45 conjugated with PerCP mAb (both from BD Pharmingen,
Erembodegem-Aalst, Belgium) or relevant isotype controls, for
45min. The labelled cells were analysed and separated using
FACS Vantage with CellQuest Pro software (Becton Dickinson).
Establishment of the gates was based on the staining profiles of the
negative controls, positive controls (SW-620 cells, labelled with
HEA) and to eliminate low forward scatter signal events,
eliminating debris, red cells and apoptotic cells.
The mAb BER-EP4 binds to a partially formol-resistant epitope
on the protein moiety of two 34- and 39kDa glycopolypeptides on
human epithelial cells. It does not bind to any non-epithelial cells
(Latza et al, 1990). Specifically, it does not bind to mesenchymal or
lymphoid tissue. However, in large cell populations antibodies can
bind in a non-specific manner. To control for this, we blocked
antibodies with 1% fetal calf serum and used isotype control
antibodies as negative controls. There is also a possibility of
immune cells expressing the HEA antigen after ingestion of
apoptotic cells. As immune cell infiltrate is a large component of
stromal tissue, we decided to use antibodies to allow us to quantify
and negatively select immune cells to avoid contamination in our
sorted epithelial fraction. Phagocyte numbers have been found to
increase from 1.5- to 2.5-fold in Duke’s B and C tumours,
respectively, and T cells by 1.4-fold in colorectal tumours (Allen
and Hogg, 1985, 1987). We decided that a combination of
antibodies binding to CD14, which is the LPS receptor and is
expressed strongly on the surface of monocytes, weakly on the
surface of granulocytes and by most tissue macrophages, and
CD45, a tyrosine phosphatase a critical requirement for T- and
B-cell antigen receptor-mediated activation, which is expressed,
typically at high levels, on all haematopoietic cells (expression is at
a higher density on lymphocytes, approximately 10% of surface
area is CD45), would be the ideal combination. It has previously
been demonstrated that using positive selection of HEA-expressing
cells and negative selection of CD45- or CD14-expressing cells
yields using immunomagnetic cell sorting lead to high yields of
epithelial cells from cell solutions (Zigeuner et al, 2000; Guo et al,
2004).
Cell sorting and confirmation of cell phenotype
A one-step, three-colour, sorting approach was used. Our goal was
to positively select colorectal parenchyma and negatively select for
stromal cells. A diagram illustrating the method is shown in
Figure 1. Sorting gates were set for positive selection of HEA
þ
CD14
  CD45
  and negative selection of HEA
  CD14
þ CD45
þ
cells. Unstained cells, cells stained with isotype controls, were used
for all samples, and SW-620 cells were used as a positive control
for CRC cells. At least 7 million HEA
þ cells were sorted, as below
this level we found RNA quantity was variable. Cells were sorted
into BD polypropylene flow tubes coated with 4% bovine serum
albumin (Sigma-Aldrich). Purity of the sample was checked after
Table 1 Microarray sample details
CEL file name Patient Sample type TNM classification Stage Location Sex Age (years)
A053-04-E1 E1 FACS T4N0M1 IV Caecum Female 68
A053-03-E6 E6 FACS T2N0Mx I Rectosigmoid Male 55
A053-05-E12 E12 FACS T3N0Mx IIA Sigmoid Male 35
A053-06-E1W E1 Whole tissue T4N0M1 IV Caecum Female 68
A053-07-E6W E6 Whole tissue T2N0Mx I Rectosigmoid Male 55
A053-08-E12W E12 Whole tissue T3N0Mx IIA Sigmoid Male 35
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ssorting by reanalysing HEA
þ CD14
  CD45
  fraction, on the same
machine, after a full cleaning protocol. Purity greater than 90% was
deemed acceptable.
After sorting, cells were confirmed to be colorectal tumour cells
by microscopic examination, by cytospinning on to Superfrost Plus
microscope slides (BDH Laboratory Supplies, Poole, UK) followed
by ethanol fixation and staining with Rapi-Diff (Cytocolor,
Hinckley, OH, USA) or immunocytochemistry. Immunocytochem-
istry was performed using Dako MNF-116 anti-pan-cytokeratin
antibody, using the standard EnVision kit protocol (Dako).
R3
R2
Region statistics
Gate: G2 Gated events: 4302
Total events: 10000 X parameter: FL1-H (Log)
Y parameter: FL2-H (Log)
Region Events % Gated % Total Px,Py
R1 3653 84.91 36.53 3, 1
R2 4302 100.00 43.02 3, 4
R3 4292 99.77 42.92 3, 4
R2
Step 1. Gating out debris and identification of HEA positive population
A
D
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C
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Step 3. R3 is set as target gate for cell sorting 
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Figure 1 This figure demonstrates our method for separating tumour stroma and parenchymal cells using fluorescence-activated cell sorting. Briefly, debrisi s
gated out, target populations identified and positively (parenchyma) or negatively selected (stroma). Dot plots represent 10000 events, and show side scatter and
forward scatter plots in Step 1 and fluorescence plots in Steps 2 and 3. Cells have been simultaneously stained with mouse anti-human anti-HEA, anti-CD14 and
anti-CD45 monoclonal antibodies conjugated with FITC, PE and PerCP, respectively, which are resolved on FL-1, FL-2 and FL-3. Step 1 demonstrates our method
of gating out debris and identification of the HEA positive population with scatter plots. Step 2 demonstrates the identification of CD45 (A) and CD14 (B)
positive populations, followed by gating of the HEA+ CD45- population (C) and gating of the HEA+ CD14- CD45- population (D). Step 3 is the identification
and the estimation of the pre-sorting parenchymal content (HEA+ CD14- CD45- population, R3 region), which is estimated at only 43% of cells in this sample,
and the selection of the R3 region as a cell sorting gate. After cell sorting the flow cytometer is cleaned, and the post-sorting populations evaluated. Step 4 shows a
histogram demonstrating the post-sorting populations of cells. The histogram plots the fluorescence of HEA
þ cells on FL-1 (region M2) against counts on the y-
axis. There is clear separation of the tumour parenchyma (M2 region) and the stromal (M1 region) cells. We estimate the populations have a purity of over9 0 % .
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parenchyma in CRC liver metastases, primary breast tumours, and
with modification, to sort breast cancer bone marrow micro-
metastases.
RNA isolation
RNA was extracted from three corresponding whole tumour
samples and FACS-purified tumour parenchyma using a modifica-
tion of the Tri Reagent (Molecular Research Center, Cincinnati,
OH, USA) protocol (Curtin and Cotter, 2004). RNA with an
absorbance ratio A260/240 41.8 and no evidence of RNA
degradation by gel electrophoresis was accepted. We then checked
the RNA quality using the Agilent Bioanalyzer (Agilent, Santa
Clara, CA, USA) runs. We used RNA with a RIN (RNA integrity
number) value X8 (Schroeder et al, 2006).
cRNA preparation
The labelling of the total RNA was performed according to the
‘Small Sample Labeling Protocol vII’ (Affymetrix, Santa Clara, CA,
USA). Total RNA (100ng) was used as starting material for the first
round of cDNA preparation. The first and second strand cDNA
synthesis was performed using the Superscript II system (Invitro-
gen, Dublin, Ireland) according to the manufacturer’s instructions
except using an oligo-dT primer containing a T7 RNA polymerase
promoter site. The first round of in vitro transcription (IVT) was
performed using the MEGAscript T7 kit (Ambion, Warrington,
UK). The second round of cDNA preparation was done as first
round except now random hexamers replaced the oligo-dT primer.
Labelled cRNA was prepared using the BioArray High Yield
RNA Transcript Labeling Kit (Enzo, Farmingdale, NY, USA).
Biotin labelled CTP and UTP (Enzo) were used in the reaction
together with unlabelled NTPs. During the labelling, the IVT
product and also the fragmented IVT product were checked by gel
electrophoresis. Following the IVT reaction, the unincorporated
nucleotides were removed using RNeasy columns (Qiagen,
Crawley, UK).
Oligonucleotide array hybridisation and scanning
Fragmented cRNA was loaded onto the GeneChip HU133 Plus 2.0
probe array cartridge (Affymetrix). The washing and staining
procedure was performed in the Affymetrix Fluidics Station 450
(Affymetrix). The biotinylated cRNA was stained with a strepta-
vidin–PE conjugate, and the probe arrays were scanned at 560nm
using a confocal laser-scanning microscope (Affymetrix Scanner
3000; Affymetrix). After hybridisation and scanning, we checked
several quality parameters: scaling factor p3-fold difference
within a study; 30/50 ratio for probe sets for GAPDH p3; present
(P) calls in the same range for all samples in the study and RawQ
below 100. All of our arrays passed all stages of the quality control.
The readings from the quantitative scanning were analysed by the
Affymetrix Gene Expression Analysis Software (Affymetrix).
Statistical analysis of gene expression data
Affymetrix GeneChip array data were normalised, pre-processed
and analysed using R and Bioconductor statistical software
(Gentleman et al, 2004). Raw CEL file data from human whole
genome Affymetrix U133Plus2 gene GeneChips of purified ‘of
whole primary’ colon cancer samples (n¼3) and tumour
parenchyma samples purified by FACS (n¼3) were imported into
R. Initial exploratory data analysis performed using the overview
function in the package made4 (Culhane et al, 2005) suggested that
the assumption of a constant sum across all microarray samples
may not be valid for these data. Moreover, there were signi-
ficantly more MAS 5.0 P calls in the whole samples than in the
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Step 4.  After cell sorting purity of the cell populations is confirmed 
Figure 1 Continued.
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were normalised using the Li and Wong’s invariant set method
using the ‘expresso’ function in the Affy package in Bioconductor
(Li and Hung Wong, 2001; Gentleman et al, 2004). Normalised data
were log2 transformed and assessed initially using use two
exploratory data analysis approaches: hierarchical cluster analysis
(1-Pearson correlation coefficient distance with average linkage
joining) and dimension reduction using correspondence analysis
(COA; Eisen et al, 1998; Fellenberg et al, 2001). Figures were
created using the made4 package in Bioconductor (Culhane et al,
2005).
Detection of genes differentially expressed in purified
tumour
Given the low number of replicates in this study, it is challenging
to estimate of gene mean and variance; therefore, rank-based non-
parametric methods may be more efficient in these data. It is
Sample Histological 
estimate (%) 
Presorting (%)  Postsorting (%)  Cell count 
(1×107)
E1 50 60.2 95.7  7 
E6 50 36.7 96.3  11 
E12 80 50.9 90.2  9 
Mean 60 49.3 94.0  9.0 
Standard
deviation  17.3 9.7  2.7  1.6 
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Figure 2 Fluorescence-activated cell sorting of CRC cells from
experimental samples. We generated single cell suspensions from three
patient samples and sorted them to greater than 90% purity in each case.
Dot plots show the pre- and post-sorting HEA
þ populations. The table
shows the estimates of tumour cell purity in the samples and the initial
histological estimates of tumour parenchyma content. We sorted an
average of 9 million cells per sample.
SW480 Sorted CRC cells from fresh tumour biopsy
MNF-116-stained CRC cells
Figure 3 Cytological confirmation of cell-sorted tumour parenchyma. To confirm that our HEA
þ CD14
  CD45
  cell population was tumour
parenchyma, we examined three post-sorting populations after cytospinning and Rapi-Diff II (Diagnostic Developments) staining and compared them to
SW-480 cells, a cell line derived from a primary colorectal tumour ( 40 magnification shown). Then we confirmed the cells were epithelial by staining with
MNF-116 pan-cytokeratin (Dako).
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Figure 4 Differential gene expression between whole tumour and cell-
sorted colorectal cancer biopsies. This graph displays the genes called as
presented by MAS 5.0 in each sample (P, present; A, absent; M, marginal).
There was a significant difference in genes called as present in the whole-
tissue samples (P¼0.0407, Student’s paired t-test). These genes are
therefore expressed in non-parenchymal (or stromal) tissue.
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sreported that rank product performs comparably or outperforms
t-statistic-based methods when replicates numbers are very low
(less than five) (Breitling et al, 2004; Jeffery et al, 2006). Rank
products analysis is a non-parametric statistic that detects genes
that are consistently highly ranked in lists, that is genes that
are consistently upregulated genes in a number of replicate
experiments. Rank products analysis does not require a measure
of gene-specific variance and is therefore particularly powerful
when only a small number of replicates are available. Rank
products analysis was performed using the Bioconductor package
RankProd. False discovery rates were estimated using 100
permutations.
To aid interpretation of these genes lists, we used DAVID to
assess which Gene Ontology biological and functional categories
Eigenvalues
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Figure 5 Hierarchical clustering using Eisen’s formula of a correlation similarity metric and average linkage clustering led to the cell-sorted samples and
whole-tissue samples clustering together, showing they are most similar to each other (A). This is despite the fact that they are paired samples.
Correspondence analysis also demonstrates that the sorted samples and whole-tissue samples cluster together (B). The first axis (horizontal) splits the
whole and FACS-purified samples. The second axis (vertical) split E1 and E1W from E6, E12, E12W and E6W. Genes that separate the samples are shown
with HUGO classification.
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used the highest stringency level, for other analyses we used an
EASE of 0.01, and false discovery rate of 1000. Heatmap images of
gene expression profiles were generated using the made4 package
in Bioconductor. The Human Genome Organisation (HUGO) gene
symbols for Affymetrix probe sets were retrieved using the annaffy
Bioconductor package and the annotation library hu133plus2
(build Tuesday, 4 October 2005, 20:53:27).
RESULTS
Patient demographics and FACS
Three matched patient biopsies were taken immediately after
resection. No patients received pre-operative chemoradiotherapy.
Metastases (m1) were observed intra-operatively in one patient.
The other patients were free from metastases (mx). Histological
examination of the E1 and E12 samples demonstrated mode-
rately differentiated adenocarcinomas with strand-like infil-
trative pattern of malignant glands through muscularis propria,
interspersed by stroma. The E6 sample demonstrated a well-
differentiated adenocarcinoma with closely packed glands invad-
ing into muscularis propria, with stroma between the glands. After
generation of single cell suspensions from our experimental
tumour biopsies, stromal content was estimated to range from
37 to 60%, and sorted to greater than 90% purity as described
earlier (Figure 2). The parenchymal component of the tumours was
estimated to range from 50 to 80% on histological assessment. The
E6 sample demonstrated the biggest discrepancy in estimation of
parenchymal content (FC estimate 37 vs 80% histological
assessment), which may be explained by the fact that the sample
Table 2 Genes called significant in whole tumour (Po0.01, rank products)
Probe set ID Gene symbol Gene title RP/Rsum pfp
207961_x_at MYH11 Myosin, heavy chain 11, smooth muscle 53.331 0
218469_at GREM1 Gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis) 18.3444 0
205594_at ZNF652 Zinc-finger protein 652 123.6405 0.0011
226663_at ANKRD10 Ankyrin repeat domain 10 122.7271 0.0013
201438_at COL6A3 Collagen, type VI, a3 113.3836 0.0014
212764_at ZEB1 Zinc finger E-box-binding homeobox 1 139.7127 0.0015
224823_at MYLK Myosin light chain kinase 108.5523 0.0017
228030_at — Transcribed locus, strongly similar to NP_005768.1 RNA-binding motif protein 6 [Homo sapiens] 138.618 0.0017
212077_at CALD1 Caldesmon 1 134.6639 0.0018
206199_at CEACAM7 Carcinoembryonic antigen-related cell adhesion molecule 7 133.868 0.002
212354_at SULF1 Sulfatase 1 93.7657 0.002
235028_at — CDNA FLJ42313 fis, clone TRACH2019425 70.702 0.0025
230269_at — Transcribed locus 145.6395 0.0029
241879_at — Transcribed locus 64.2024 0.0033
227260_at ANKRD10 Ankyrin repeat domain 10 201.5746 0.0064
227061_at — CDNA FLJ44429 fis, clone UTERU2015653 209.8229 0.0066
202202_s_at LAMA4 Laminin, a4 200.6896 0.0067
218468_s_at GREM1 Gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis) 194.7291 0.0067
238750_at — Transcribed locus 211.7612 0.0067
225269_s_at C2orf12 Chromosome 2 open-reading frame 12 183.4678 0.0068
227140_at — CDNA FLJ11041 fis, clone PLACE1004405 197.6319 0.0068
203691_at PI3 Peptidase inhibitor 3, skin-derived (SKALP) 200.1168 0.0069
208747_s_at C1S Complement component 1, s subcomponent 194.1383 0.007
221748_s_at TNS1 Tensin 1 185.7447 0.007
225681_at CTHRC1 Collagen triple helix repeat containing 1 215.9928 0.0071
1557270_at — CDNA FLJ36375 fis, clone THYMU2008226 171.7643 0.0072
202404_s_at COL1A2 Collagen, type I, a2 191.9636 0.0073
225786_at LOC284702 Hypothetical protein LOC284702 162.5829 0.0073
225664_at COL12A1 Collagen, type XII, a1 166.478 0.0075
243134_at — Transcribed locus 219.3881 0.0075
210809_s_at POSTN Periostin, osteoblast-specific factor 188.6781 0.0076
225275_at EDIL3 EGF-like repeats and discoidin I-like domains 3 171.1717 0.0076
221729_at COL5A2 Collagen, type V, a2 231.1445 0.0086
202948_at IL1R1 Interleukin 1 receptor, type I 252.7068 0.0087
225107_at HNRNPA2B1 Heterogeneous nuclear ribonucleoprotein A2/B1 243.1025 0.0087
226731_at PELO Pelota homolog (Drosophila) 246.3912 0.0087
209656_s_at TMEM47 Transmembrane protein 47 230.2568 0.0088
218353_at RGS5 Regulator of G-protein signaling 5 254.393 0.0088
224565_at TncRNA Trophoblast-derived noncoding RNA 273.7687 0.0088
212067_s_at C1R Complement component 1, r subcomponent 241.6854 0.0089
201852_x_at COL3A1 Collagen, type III, a1 (Ehlers-Danlos syndrome type IV, autosomal dominant) 271.8757 0.009
208782_at FSTL1 Follistatin-like 1 268.8627 0.009
212353_at SULF1 Sulfatase 1 265.4504 0.0091
221778_at JHDM1D Jumonji C domain containing histone demethylase 1 homolog D (S. cerevisiae) 229.742 0.0091
224694_at ANTXR1 Anthrax toxin receptor 1 268.3533 0.0091
225809_at DKFZP564O0823 DKFZP564O0823 protein 261.4881 0.0091
215076_s_at COL3A1 Collagen, type III, a1 (Ehlers-Danlos syndrome type IV, autosomal dominant) 240.3341 0.0092
1555878_at RPS24 Ribosomal protein S24 260.4235 0.0093
201540_at FHL1 Four-and-a-half LIM domains 1 258.0377 0.0093
231579_s_at TIMP2 TIMP metallopeptidase inhibitor 2 265.3035 0.0093
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scontained a large muscularis propria component, which could
account for the high proportion of non-staining FC events. Sorted
cells were subsequently confirmed as tumour parenchyma by
light microscopy assessment (Figure 3). We found the sorted
cell population was homogenous and had the morphological
appearances consistent with CRC cells after staining with Rapi-Diff
and comparison to SW-620 colorectal cell line. The cells also
stained positive for the cytokeratin MNF-116, confirming they
were epithelial in nature. Using FC we found that the population of
HEA
þ cells fluoresced in the same region as cells stained with
MNF-116.
Differential gene expression
There were significantly more MAS 5.0 P calls in the whole samples
than in the FACS-purified samples (paired t-test, Po0.05;
Figure 4). Ordination was used to explore the data, and
correspondence analysis was applied to the data using the made4
package in Bioconductor (Culhane et al, 2005). Correspondence
analysis is a useful dimension reduction method for observing the
w
2 or associations between genes and samples. The dendrogram
showed that the whole and the purified samples could be portioned
into two distinct clusters (Figure 5A). These clusters were also
observed on the most variant or first axis of a COA of these data
(Fellenberg et al, 2001) (Figure 5B). Interestingly, the second most
variant axis (F2, vertical) separated the metastatic (E1) and
metastatic-free samples. Although we have few replicates in this
study, it appeared that metastatic and metastatic-free tumour
samples were more defined in the purified samples when
compared to the whole samples. The discrimination between
metastatic and metastatic-free samples accounted for more
variance than difference between tumour stage.
Expression of 289 genes were detected in whole-biopsy samples
but not in purified samples (Po0.05). Of these, 50 differentially
expressed genes were highly significant (Po0.01; Table 2).
Expression of 103 genes were detected in purified samples, but
significantly downregulated in whole samples (Po0.05), of which
33 of these were significant at Po0.01 (Table 3) which are
displayed in the Heatmaps in. Heatmaps of the highly significant
differentially expressed genes were generated, and displayed in
Figure 6.
Functional annotation
We used DAVID to classify gene function in the whole tumour
sample (Table 4). Most functional classes are consistent
with stromal as opposed to tumour cell function (e.g., protein-
aceous extracellular matrix P¼2.37 10
 08, extracellular matrix
P¼2.49 10
 08, collagen triple helix repeat P¼7.12 10
 07),
although genes known to be expressed in tumour epithelium were
identified (e.g., GREM1). Looking at individual genes, upregulation
of connective tissue genes was prevalent (e.g., COL6A3, COL1A2,
COL12A1, COL5A2, COL3A1, CTHRC1, SULF1), as were genes
involved in extracellular matrix function (e.g., LAMA4, PI3,
POSTN, TIMP2) and cell adhesion (e.g., TNS1). Genes involved
in endothelial function (e.g., TIMP2) and specifically, colon cancer
tumour endothelium, such as the anthrax toxin receptor
(ANTXR1), were also upregulated (Liu et al, 2008).
Table 3 Genes called significant in FACS purified CRC cells (Po0.01, rank products)
Probe set ID Gene symbol Gene title RP/Rsum pfp
200664_s_at DNAJB1 DnaJ (Hsp40) homolog, subfamily B, member 1 68.0709 0
204018_x_at HBA1 Haemoglobin, a1 66.0374 0
209116_x_at HBB Haemoglobin, b 10.5524 0
209458_x_at HBA1 Haemoglobin, a1 60.4785 0
211699_x_at HBA1 Haemoglobin, a1 67.0989 0
211745_x_at HBA1 Haemoglobin, a1 52.9371 0
214414_x_at HBA1 Haemoglobin, a1 61.1365 0
217232_x_at HBB Haemoglobin, b 8.1213 0
217316_at OR7A10 Olfactory receptor, family 7, subfamily A, member 10 59.4448 0
217414_x_at HBA1 Hemoglobin, a1 28.7839 0
225762_x_at LOC284801 Hypothetical protein LOC284801 9.059 0
225767_at — — 42.7413 0
229667_s_at HOXB8 Homeobox B8 34.4176 0
204419_x_at HBG1 Haemoglobin, gA 97.798 0.0012
1565817_at IKZF1 IKAROS family zinc-finger 1 (Ikaros) 93.4767 0.0013
211696_x_at HBB Haemoglobin, b 92.8953 0.0013
209795_at CD69 CD69 molecule 92.588 0.0014
231100_at RRAD Ras-related associated with diabetes 135.6185 0.0044
207574_s_at GADD45B Growth arrest and DNA-damage-inducible, b 152.1069 0.0052
208252_s_at CHST3 Carbohydrate (chondroitin 6) sulfotransferase 3 149.7873 0.0052
212099_at RHOB Ras homolog gene family, member B 151.4472 0.0055
225377_at C9orf86 Chromosome 9 open-reading frame 86 145.8861 0.0055
230935_at — — 144.722 0.0058
243001_at C18orf22 Chromosome 18 open-reading frame 22 167.4874 0.006
202768_at FOSB FBJ murine osteosarcoma viral oncogene homolog B 163.3693 0.0062
210042_s_at CTSZ Cathepsin Z 174.6238 0.0062
1569428_at WIBG Within bgcn homolog (Drosophila) 190.2299 0.0071
206834_at HBB Haemoglobin, b 203.1012 0.0073
1556262_at — CDNA clone IMAGE:4822139 208.8925 0.0074
220369_at SMEK1 SMEK homolog 1, suppressor of mek1 (Dictyostelium) 189.2357 0.0074
244804_at SQSTM1 Sequestosome 1 210.7027 0.0075
235102_x_at — Transcribed locus 199.6653 0.0076
213515_x_at HBG1 Haemoglobin, gA 223.858 0.0088
237518_at — Transcribed locus 225.91 0.0091
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sIn contrast, the 31 highly significantly expressed genes in the
FACS-purified cells do not display characteristics of stromal gene
expression, and may be representative of tumour parenchyma gene
expression. Genes involved in cell signalling, such as SQSTM1,
which regulates activation of the nuclear factor-kB (NF-kB)
signalling pathway, receptor internalisation, and protein turnover,
and RRAD, a member of the Ras/GTPase superfamily, are also
overexpressed (Moyers et al, 1997; Seibenhener et al, 2007). Genes
known to be expressed in CRC were also significantly upregulated,
such as HOX2D and RHOB, which mediate apoptosis in neoplastic
cells, and are targets for novel antitumour agents, such as
farnesyltransferase inhibitors (Vider et al, 1997; Delarue et al,
2007).
Comparison with Kwong et al expression signature
Kwong et al (2005) examined the expression signature derived
from 60 tumours (normal mucosa, adenoma, tumour and liver
metastases) and identified an expression profile that was able to
differentiate between normal and neoplastic samples, but not
individual tumour stages. They suggested that stromal genes may
obscure the subtle molecular changes in tumours of differing
pathological stage. Examination of their gene list, specifically the
34 upregulated genes in their signature, reveals the expression of
extracellular matrix proteins such as, collagen, type I, a1( COL1A1)
and fibronectin. The authors believe this represented gene
expression derived from infiltrating lymphocytes and other
stroma. The gene list they identified shares similarities to gene
expressed in our whole tumour sample (ANTXR1, COL12A1,
COL5A2, CTHRC1, POSTN).
DISCUSSION
Our study demonstrates that it is feasible to reproducibly
separate and purify tumour parenchyma and other cell popula-
tions from a single cell suspension generated from a solid tumour
using FACS. We also found that the gene expression profile elicited
from the whole tumour was significantly different from that of the
purified tumour parenchyma, and that source of this differential
expression may be tumour stroma. When tumour parenchymal
purity is necessary, FACS may be an alternative to LCM, in
particular in tumours such as CRC, melanoma and other non-
sclerotic tumours amenable to the generation of a single cell
suspension.
In our samples, we noted a large variance in estimated quantity
of tumour parenchyma and stroma. Using FC we estimated that
the parenchymal component of the tumours ranged from 37 to
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Figure 6 Genes detected by rank products analysis (Po0.01). Heatmaps showing the differentially expressed genes detected in whole but not purified
samples (A) and purified but not whole samples (B) using rank product analysis (Po0.01) using Z-score normalised values (row centred). Red tiles
represent upregulated genes and blue represent downregulated genes.
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s60% and stroma from 40 to 63%. This was enriched to over 90%
(range 90–96%) in each case with one sorting run per sample after
calibration of the machine and settings for each sample.
Verification of cell type is straightforward with standard staining
techniques. We believe this level of stroma would grossly affect the
gene expression profile taken from the biopsy and would be in
keeping with the findings of Sugiyama et al (2002).
For publication we specifically used rank products as this has
been shown to be reliable in small sample sizes in microarray
experiments (Breitling et al, 2004; Jeffery et al, 2006). We found
that the expression profile in the whole elicited also made
biological sense. We are confident that there are real differences
in the gene identified, which are related to the stromal gene
expression, and that this has implications for clinical application
of gene expression microarrays in CRC.
The MammaPrint assay, which is a clinical application of the
van‘t Veer 70-gene breast cancer expression profile, relies on a
single fresh sample of tumour to predict prognosis (van ‘t Veer
et al, 2002; Cardoso et al, 2008). The samples are examined, and a
stromal content of o50% is deemed acceptable for the test. This
would arguably eliminate two of our samples from analysis, which
we were able to enrich to 490% purity. However, Wang et al
(2004), who derived an expression profile predicting recurrence of
Duke’s B colorectal carcinoma, included only samples that were
enriched to over 85% purity. We believe that in CRC samples, the
stroma will contaminate the sample causing problems with patient
classification, but that can be overcome with parenchymal
purification. The optimal tumour/stroma ratio for gene expression
studies is yet to be determined and may vary depending on the
tumour type.
To ensure good quality expression data, we used several
layers of quality control, starting with RNA gel electrophoresis
and then checking RNA integrity with the Agilent Bioanalyzer
(Agilent). Subsequently, after hybridisation and scanning, we
checked several quality parameters such as scaling factor, 30/50
ratios, P calls and RawQ values. Quantitative RT–PCR was not
employed as all of our arrays passed all stages of the quality
control, and we do not believe that it will be used in clinical
practice. This has been borne out by the current application of the
MammaPrint assay and is a similar approach to other clinical
microarray studies (Wang et al, 2004; Glas et al, 2006; Ach et al,
2007; Cardoso et al, 2008).
We found a significant difference in the total number of probes
called as present using the Affymetrix MAS5 signal algorithm. This
shows that the whole tissue expressed a larger number of genes
than sorted cells, demonstrating the wide range of genes expressed
by non-tumour cells. We used Li and Wong’s invariant set method
for normalisation of the data sets (Li and Hung Wong, 2001). This
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suses a set of non-differentially expressed genes to normalise data
that are identified by using an iterative procedure. Gene expression
common to the sorted cells and whole tissue should be reasonably
uniform. Any genes found to be expressed in the whole tissue can
be presumed to be contained in stromal tissue. We then sought to
examine how similar the gene expression profile of each sample
was. Using hierarchical clustering, all three sorted samples
clustered together, as did the whole-tissue samples clustered
together. Correspondence analysis also showed a clear separation
of sorted samples and whole-tissue samples. The E1 and E1W
sample also separated from the other samples. This is not
surprising as this sample was from a more advanced tumour than
the others. The stromal component of the whole-tissue sample
was the biggest determinate in differences and could easily
separate all samples. This may explain why some studies show
very similar GEP throughout tumour stages, and the similarity of
some of the genes in our whole tumour sample to that of Kwong
et al (Birkenkamp-Demtroder et al, 2002; Kwong et al, 2005).
Qualitatively the expression of the whole tumour samples were
consistent with tumour stroma, with genes highly specific for
colorectal tumour stroma (e.g., ANTXR1), and DAVID analysis
identifying highly significant functional groups involved in
Table 4 Functional classification of whole tumour gene expression with DAVID (top 50)
Category Term Gene count Percentage P-value
GO_CC Extracellular region part 15 32.61% 3.87E 10
GO_CC Extracellular region 17 36.96 6.31E 10
SP_PIR Hydroxylation 7 15.22 5.82E 09
GO_CC Proteinaceous extracellular matrix 10 21.74 2.37E 08
SP_PIR Extracellular matrix 9 19.57 2.49E 08
GO_CC Extracellular matrix 10 21.74 2.71E 08
SP_PIR Signal 22 47.83 3.88E 08
GO_CC Extracellular matrix part 7 15.22 1.00E 07
UP_SEQ Signal peptide 22 47.83 1.49E 07
SP_PIR Trimer 5 10.87 3.61E 07
INTERPRO Collagen triple helix repeat 6 13.04 7.12E 07
SP_PIR Triple helix 5 10.87 7.53E 07
SP_PIR Hydroxylysine 5 10.87 8.60E 07
SP_PIR Secreted 15 32.61 8.62E 07
GO_BP Phosphate transport 6 13.04 9.47E 07
SP_PIR Hydroxyproline 5 10.87 1.10E 06
GO_CC Collagen 5 10.87 1.22E 06
SP_PIR Collagen 6 13.04 1.24E 06
SP_PIR Direct protein sequencing 18 39.13 2.48E 06
SP_PIR Pyroglutamic acid 5 10.87 3.81E 06
SP_PIR Structural protein 6 13.04 6.91E 06
INTERPRO Collagen helix repeat 5 10.87 7.04E 06
GO_BP Organic anion transport 6 13.04 1.73E 05
GO_BP Anion transport 6 13.04 3.99E 05
GO_MF Extracellular matrix structural constituent 5 10.87 6.54E 05
KEGG ECM-receptor interaction 5 10.87 7.67E 05
UP_SEQ Short sequence motif:Cell attachment site 5 10.87 9.21E 05
PIR_SUPERFAMILY Collagen a1(I) chain 3 6.52 9.79E 05
KEGG Focal adhesion 6 13.04 1.39E 04
SP_PIR Glycoprotein 19 41.30 1.57E 04
GO_BP System development 13 28.26 1.62E 04
GO_MF Structural molecule activity 9 19.57 1.68E 04
UP_SEQ Propeptide:C-terminal propeptide 3 6.52 1.83E 04
SP_PIR Ehlers-Danlos syndrome 3 6.52 1.89E 04
GO_BP Organ development 11 23.91 2.43E 04
GO_BP Extracellular matrix organization and biogenesis 4 8.70 2.45E 04
GO_CC Fibrillar collagen 3 6.52 2.71E 04
INTERPRO Fibrillar collagen, C-terminal 3 6.52 2.84E 04
KEGG Cell communication 5 10.87 4.06E 04
GO_BP Multicellular organismal development 14 30.43 5.90E 04
GO_BP Multicellular organismal process 17 36.96 6.33E 04
UP_SEQ Disulphide bond 15 32.61 6.92E 04
SMART COLFI 3 6.52 7.14E 04
UP_SEQ Glycosylation site:N-linked (GlcNAcy) 18 39.13 8.15E 04
GO_BP Anatomical structure development 13 28.26 0.001069024
UP_SEQ Domain:VWFC 3 6.52 0.001162772
GO_BP Extracellular structure organization and biogenesis 4 8.70 0.001291298
INTERPRO von Willebrand factor, type C 3 6.52 0.003487936
GO_BP Developmental process 15 32.61 0.004413792
GO_MF Complement component C1s activity 2 4.35 0.004676533
GO_CC Extracellular space 6 13.04 0.005323916
UP_SEQ Domain:VWFA 4 2 4.35 0.006011568
SMART VWC 3 6.52 0.007203275
SP_PIR Pyrrolidone carboxylic acid 3 6.52 0.008914529
SP_PIR Skin 2 4.35 0.009320842
Differential gene expression in CRC parenchyma and stroma
MJ Smith et al
1462
British Journal of Cancer (2009) 100(9), 1452–1464 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sextracellular matrix function. Conversely, FACS-purified paren-
chyma expressed genes specifically associated with colorectal
neoplasia, such as HOX2D and RHOB. The ability to examine the
samples in parallel affords increased precision in analysis of
tumour fraction gene expression and offers new opportunities to
examine tumour–stroma interactions.
Fluorescence-activated cell sorting parenchymal purification has
several advantages over LCM. Disaggregation of a tumour sample
generates a large random sample of tumour cells and may elicit a
more representative and relevant gene expression profile than
LCM, without the need for RNA amplification. Previous studies
have assessed the differences between LCM acquired tissue,
macrodissection and whole-tissue samples for microarray studies
(Sugiyama et al, 2002; Michel et al, 2003; de Bruin et al, 2005).
Sugiyama suggests that if the stromal compartment is 430% LCM
should be used, and showed marked differences in GEP in LCM-
derived tissue compared with bulk biopsy. Similarly, Michel et al
(2003) demonstrated that the LCM process introduces a bias into
GEP profiles. Although they found that large expression changes
were maintained, many genes changed with lower expression levels
may be lost. This is problematic for several reasons – particularly as
smaller changes in mRNA expression may have larger effects
downstream than larger ones. Also it makes comparisons difficult
between studies. Although LCM aims to overcome such problems,
the very premise it is built on may introduce bias. A two-
dimensional microscope view of a complex three-dimensional
structure such as a tumour leads to irreversible qualitative and
quantitative loss of information (Nyengaard, 1999). This means that
fractions of cells can be grossly under- or overestimated if unbiased
sampling methods such as stereological methods are not used (the
‘reference trap’). At worst it can lead to a gene expression profile of
a tiny fraction of tumour being misinterpreted as expression of the
whole tumour. Macrodissection is subject to similar compromises.
Fluorescence-activated cell sorting overcomes many of these
problems by allowing systematic sampling of cells, providing a
large sample of cells, which allows confirmation of purity of targets
and also a better average of gene expression in a tumour.
In conclusion, FACS is effective in producing homogenous cell
populations for gene expression microarray experiments in solid
tumours and is viable alternative to macrodissection, LCM and
whole tumour sampling in microarray experiments. Fluorescence-
activated cell sorting overcomes many of the practical and
theoretical problems associated with LCM. The gene expression
profile of FACS-purified tumour parenchyma is significantly
different to that of clinically resected tumour biopsies. Our
analysis suggests that stromal gene expression is responsible for
the differential expression and makes a significant contribution to
the gene expression profile of whole tumour CRC biopsies.
Therefore, one should consider a purification strategy when
planning solid tumour gene expression microarray experiments.
Although many of the sources of technical noise and variation in
gene expression microarray technology have been overcome, there
remain challenges, such as the approach to tumour heterogeneity,
which need to be overcome before it is accepted into clinical
practice.
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